These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9457495)

  • 21. [A 12-month oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 2-month recovery test].
    Yoshida M; Kawaminami A; Tawaratani T; Ishibashi S; Nakazawa M; Kitayama E; Oka T; Adachi T; Iwakura K; Sumi N
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():147-75. PubMed ID: 9170606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval.
    Stewart DA; Taylor J; Ghosh S; Macphee GJ; Abdullah I; McLenachan JM; Stott DJ
    Eur J Clin Pharmacol; 1992; 42(6):577-80. PubMed ID: 1623896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Polymorph ventricular tachycardia with torsades de pointes caused by administration of terodiline (Mictrol)].
    van der Klauw MM; van Rey FJ; Stricker BH
    Ned Tijdschr Geneeskd; 1992 Jan; 136(2):91-3. PubMed ID: 1370730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 2nd communication: tissue levels and enzyme activity in rats after repeated administration, and placental and milk transfer after single administration.
    Nakamura A; Hirota T; Sugihara K; Watanabe S; Tougou K; Morino A; Ezumi Y; Takaichi M
    Arzneimittelforschung; 1997 Feb; 47(2):160-8. PubMed ID: 9079235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Block and modified gating of cardiac calcium channel currents by terodiline.
    Ogura T; Jones S; Shuba LM; McCullough JR; McDonald TF
    Br J Pharmacol; 1999 Aug; 127(8):1837-45. PubMed ID: 10482914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.
    Jones SE; Shuba LM; Zhabyeyev P; McCullough JR; McDonald TF
    Br J Pharmacol; 2000 Sep; 131(2):245-54. PubMed ID: 10991917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A 26-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats followed by a 9-week recovery test].
    Okasaki K; Baba S; Ikeda H; Chihaya Y; Satake S; Nagata R; Ishibashi S; Iwakura K; Sumi N
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():59-92. PubMed ID: 9170603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antigenicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence].
    Okasaki K; Nagata R; Ohnishi M; Samejima H; Fujisawa H; Kimura K
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():307-13. PubMed ID: 9170617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline.
    Jones SE; Ogura T; Shuba LM; McDonald TF
    Br J Pharmacol; 1998 Nov; 125(6):1138-43. PubMed ID: 9863639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereoselective cardiotoxic effects of terodiline.
    Hartigan-Go K; Bateman DN; Daly AK; Thomas SH
    Clin Pharmacol Ther; 1996 Jul; 60(1):89-98. PubMed ID: 8689817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency.
    Sasaki Y; Hamada K; Yamazaki C; Seto T; Kimura Y; Ukai Y; Yoshikuni Y; Kimura K
    Int J Urol; 1997 Jul; 4(4):401-6. PubMed ID: 9256331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Single-dose toxicity studies of (+/-)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, in mice, rats and dogs].
    Nishiguchi Y; Yoshida M; Tarui M; Nakazawa M; Oka T; Iwakura K; Sumi N
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():1-13. PubMed ID: 9170600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actions of terodiline, its isomers and main metabolite on isolated detrusor muscle from rabbit and man.
    Andersson KE; Ekström B; Mattiasson A
    Pharmacol Toxicol; 1988 Nov; 63(5):390-5. PubMed ID: 3237596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A 13-week oral repeated dose toxicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in dogs followed by a 5-week recovery test].
    Yoshida M; Oka T; Tawaratani T; Ishibashi S; Nakazawa M; Kitayama E; Adachi T; Iwakura K; Sumi N
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():125-46. PubMed ID: 9170605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacology of terodiline.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1984; 87():13-20. PubMed ID: 6599419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Terodiline in children with diurnal enuresis.
    Elmér M
    Scand J Urol Nephrol Suppl; 1984; 87():59-61. PubMed ID: 6599420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The mechanism of increased thyroidal function caused by (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21), a novel drug for urinary frequency and incontinence, administration in rats].
    Ishibashi S; Nakazawa M; Tawaratani T; Yoshida M; Tamura H; Adachi T; Kawaguchi K; Iwakura K; Sumi N; Wakabayashi K
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():187-99. PubMed ID: 9170608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year dietary carcinogenicity study of (+/-)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats.
    Hatch RC; Regan KS; Ishibashi S; Nakazawa M; Iwakura K; Sumi N
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():289-306. PubMed ID: 9170616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seventy-eight-week dietary carcinogenicity study of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice.
    Hatch RC; Regan KS; Ishibashi S; Nakazawa M; Iwakura K; Sumi N
    J Toxicol Sci; 1997 Apr; 22 Suppl 1():275-87. PubMed ID: 9170615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline.
    Shuba LM; Kasamaki Y; Jones SE; Ogura T; McCullough JR; McDonald TF
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1417-26. PubMed ID: 10454521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.